| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
23,510,000 |
| Market
Cap: |
238.39(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.42 - $19.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Tactile Systems Technology is a medical technology company that develops and provides medical devices for the treatment of chronic diseases. Co. is the manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Co. provides its products for use in the home and sells or rents them through vascular, wound and lymphedema clinics throughout the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
9,370 |
65,788 |
67,338 |
98,056 |
| Total Sell Value |
$91,903 |
$902,331 |
$922,594 |
$1,391,824 |
| Total People Sold |
3 |
5 |
6 |
6 |
| Total Sell Transactions |
3 |
9 |
10 |
22 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Birkemeyer Elaine M. |
Chief Financial Officer |
• • – |
2025-05-12 |
4 |
AS |
$9.94 |
$29,037 |
D/D |
(2,921) |
99,111 |
|
6% |
|
| Dodd Sheri Louise |
Chief Executive Officer |
• • – |
2025-05-08 |
4 |
S |
$9.83 |
$30,955 |
D/D |
(3,149) |
181,241 |
|
-6% |
|
| Burke William W |
Director |
• • – |
2025-05-08 |
4 |
AS |
$9.67 |
$31,911 |
D/D |
(3,300) |
48,520 |
|
6% |
|
| Diersen Carmen L |
Director |
• • – |
2025-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,078 |
37,698 |
|
- |
|
| Shafer David Brent |
Director |
• • – |
2025-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,078 |
48,822 |
|
- |
|
| Washington Boyd Vindell |
Director |
• • – |
2025-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,078 |
35,247 |
|
- |
|
| Burke William W |
Director |
• • – |
2025-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,078 |
51,820 |
|
- |
|
| Huggenberger Raymond |
Director |
• • – |
2025-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,078 |
56,320 |
|
- |
|
| King Laura G. |
Director |
• • – |
2025-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,078 |
19,048 |
|
- |
|
| Asbury Valerie L. |
Director |
• • – |
2025-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,078 |
48,822 |
|
- |
|
| Reuvers Daniel L. |
Director |
• • – |
2025-03-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
68,162 |
68,162 |
|
- |
|
| Reuvers Daniel L. |
Director |
• • – |
2025-03-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
68,162 |
146,442 |
|
- |
|
| Burns Kristie |
Sr. VP Mktg & Clinical Affairs |
• • – |
2025-02-25 |
4 |
S |
$14.40 |
$93,160 |
D/D |
(6,468) |
77,540 |
|
29% |
|
| Birkemeyer Elaine M. |
Chief Financial Officer |
• • – |
2025-02-25 |
4 |
AS |
$14.51 |
$29,980 |
D/D |
(2,066) |
102,032 |
|
-29% |
|
| Reuvers Daniel L. |
Director |
• • – |
2025-02-25 |
4 |
AS |
$14.18 |
$401,850 |
D/D |
(28,338) |
214,604 |
|
-29% |
|
| Reuvers Daniel L. |
Director |
• • – |
2025-02-24 |
4 |
AS |
$14.55 |
$159,147 |
D/D |
(10,938) |
242,942 |
|
-31% |
|
| Burns Kristie |
Sr. VP Mktg & Clinical Affairs |
• • – |
2025-02-24 |
4 |
S |
$14.65 |
$70,753 |
D/D |
(4,830) |
84,008 |
|
31% |
|
| Birkemeyer Elaine M. |
Chief Financial Officer |
• • – |
2025-02-24 |
4 |
AS |
$14.70 |
$55,538 |
D/D |
(3,778) |
104,098 |
|
-31% |
|
| Reuvers Daniel L. |
Director |
• • – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
15,853 |
253,880 |
|
- |
|
| Burns Kristie |
Sr. VP Mktg & Clinical Affairs |
• • – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
24,069 |
88,838 |
|
- |
|
| King Laura G. |
Director |
• • – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,970 |
2,970 |
|
- |
|
| Birkemeyer Elaine M. |
Chief Financial Officer |
• • – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
46,581 |
107,876 |
|
- |
|
| Dodd Sheri Louise |
Chief Executive Officer |
• • – |
2025-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
85,777 |
184,390 |
|
- |
|
| Ferstler Sherri Lee |
Senior VP, Sales |
• • – |
2024-08-12 |
4 |
S |
$13.07 |
$20,263 |
D/D |
(1,550) |
38,764 |
|
-33% |
|
| Dodd Sheri Louise |
Chief Executive Officer |
• • – |
2024-08-07 |
4 |
A |
$0.00 |
$0 |
D/D |
64,959 |
98,613 |
|
- |
|
630 Records found
|
|
Page 1 of 26 |
|
|
0.20 (1.93%) 
